STOCK TITAN

Absci Corporation - ABSI STOCK NEWS

Welcome to our dedicated page for Absci Corporation news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci Corporation stock.

Absci Corporation (Nasdaq: ABSI) is a leading company that leverages the power of artificial intelligence to drive the next generation of drug discovery and development. Based in Vancouver, WA, Absci combines advanced AI technology with scalable wet lab processes, aiming to revolutionize the speed and efficacy of creating novel biologics.

Absci's core business revolves around its Integrated Drug Creation™ platform, which offers a unified approach to biologic drug discovery and cell line development. By optimizing multiple drug characteristics simultaneously, this platform accelerates the timeline from concept to clinic while increasing the probability of success in therapeutic development. The company is uniquely positioned to screen billions of cells per week, enabling rapid transformation from AI-designed antibodies to wet lab-validated candidates in as little as six weeks.

Recent achievements include the presentation of positive preclinical data for ABS-101, a potential best-in-class anti-TL1A antibody program. The company has initiated IND-enabling studies and plans to submit an Investigational New Drug application in the first quarter of 2025. Additionally, Absci has forged strategic partnerships, such as a high-profile collaboration with AstraZeneca aimed at advancing an AI-designed oncology candidate, potentially valued at up to $247 million.

Financially, Absci has strengthened its balance sheet through successful public offerings, raising approximately $86 million in gross proceeds. This financial boost ensures the company has the resources needed to advance its internal programs and continue investment in its groundbreaking platform.

Absci's innovative approach and commitment to leveraging AI for drug discovery have not only enhanced its internal pipeline but also attracted significant industry partnerships. The company’s vision of delivering breakthrough therapeutics at the click of a button continues to drive its mission forward, promising better and faster solutions for patients worldwide.

Rhea-AI Summary
Absci (Nasdaq: ABSI) appoints Professor Sir Menelas 'Mene' Pangalos, a distinguished biopharmaceutical executive, to its Board of Directors and as co-chair of Absci’s Scientific Advisory Board. Sir Pangalos, with over 25 years of experience in drug discovery and development, joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. His appointment follows the recent addition of former Phillips CEO Frans van Houten to the Board. Absci’s recent collaborations with AstraZeneca and Almirall underscore its commitment to leveraging AI to bring impactful drugs to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
management
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) announced positive preclinical data for ABS-101, a potential best-in-class anti-TL1A antibody program, at the 42nd Annual J.P. Morgan Healthcare Conference. The company's generative AI platform designed over 50 antibody leads with subnanomolar affinity, selecting three potential candidates for the ABS-101 program. The preclinical studies demonstrated properties consistent with a potentially superior product profile, supporting the program’s potential to create an efficacious candidate conducive to subcutaneous dosing. Absci expects to initiate Investigational New Drug application (IND) enabling studies for ABS-101 in February 2024, and submit an IND in the first quarter of 2025. Subject to clearance of the IND, Absci expects to initiate Phase 1 studies for this program shortly thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.47%
Tags
conferences clinical trial
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) to participate in 26th Annual Needham Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
conferences
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
conferences
-
Rhea-AI Summary
Absci (Nasdaq: ABSI) and PrecisionLife collaborate to develop a joint portfolio of potential therapeutics addressing unmet medical needs. The partnership aims to create a pipeline of novel biotherapeutics for chronic diseases. Absci achieves its 2023 outlook of ten new Active Programs signed for the year through this collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
partnership AI
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) collaborates with AstraZeneca to develop an AI-designed antibody for oncology. The collaboration combines Absci's generative AI technology with AstraZeneca's expertise, aiming to accelerate the discovery of a potential new cancer treatment candidate. The agreement includes an upfront commitment, R&D funding, milestone payments, and royalties on product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.64%
Tags
AI
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) to present at Piper Sandler 35th Annual Healthcare Conference in New York, NY. The company's management will present on November 29th at 10:50 a.m. Eastern Time. Interested parties can access a live and archived webcast on the company’s investor relations website at investors.absci.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) entered into a partnership with Almirall to rapidly develop novel treatments for dermatological diseases, with a deal value of up to $664M plus royalties. They also unveiled an AI drug creation pipeline of four wholly-owned assets. The company reported financial and operating results for the quarter ended September 30, 2023, highlighting their recent achievements and the value of their AI Integrated Drug Creation™ platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) and Almirall S.A. (BME: ALM) announced a partnership to develop AI-designed therapeutics for chronic dermatological diseases. Absci's de novo generative AI technology will be used to create and commercialize therapeutic candidates for two dermatological targets, with potential upfront fees, R&D, and post-approval milestone payments of up to $650 million. The collaboration aims to deliver life-changing medicines to patients and represents Almirall's first de novo AI drug collaboration, marking a significant advancement in AI drug creation for dermatology and chronic inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12%
Tags
partnership AI
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) will be participating in upcoming investor conferences in New York, NY. They will be hosting 1x1 meetings on November 8th and participating in fireside chats on November 15th and 16th. Interested parties can access webcasts on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences

FAQ

What is the current stock price of Absci Corporation (ABSI)?

The current stock price of Absci Corporation (ABSI) is $4 as of November 4, 2024.

What is the market cap of Absci Corporation (ABSI)?

The market cap of Absci Corporation (ABSI) is approximately 449.7M.

What does Absci Corporation specialize in?

Absci specializes in using artificial intelligence and scalable wet lab technologies to accelerate the creation of novel biologics for therapeutic use.

What is Absci's Integrated Drug Creation™ platform?

The Integrated Drug Creation™ platform optimizes multiple drug characteristics simultaneously, speeding up the transition from concept to clinic and increasing the probability of success in development.

What are some of Absci's recent achievements?

Recent achievements include presenting positive preclinical data for ABS-101, initiating IND-enabling studies, and partnering with AstraZeneca for an AI-designed oncology candidate.

How has Absci strengthened its financial position?

Absci has strengthened its financial position through public offerings, raising approximately $86 million in gross proceeds to fund its internal programs and platform investments.

What is the significance of Absci's collaboration with AstraZeneca?

The collaboration with AstraZeneca combines Absci's AI drug creation platform with AstraZeneca's oncology expertise, aiming to advance a new AI-designed cancer treatment candidate valued at up to $247 million.

Where are Absci's main operational facilities located?

Absci's headquarters is in Vancouver, WA, with an AI Research Lab in New York City and an Innovation Center in Zug, Switzerland.

What is the timeline for ABS-101's clinical trials?

Absci expects to submit an IND for ABS-101 in the first quarter of 2025 and initiate Phase 1 clinical studies shortly thereafter.

How does Absci's AI technology contribute to drug discovery?

Absci's AI technology enables rapid screening and design of drug candidates, optimizing multiple characteristics important to both development and therapeutic benefit, thus accelerating the overall drug discovery process.

What are some of the internal programs Absci is focusing on?

Absci is focusing on several internal programs, including ABS-101 for anti-TL1A, ABS-201 for dermatology, and ABS-301 for immuno-oncology, alongside advancing additional internal asset programs.

How can interested parties stay updated on Absci's developments?

Interested parties can stay updated by visiting Absci's website and investor relations page, where they routinely post investor presentations, SEC filings, press releases, and webcasts.

Absci Corporation

Nasdaq:ABSI

ABSI Rankings

ABSI Stock Data

449.68M
113.56M
20.32%
61.12%
11.64%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States of America
VANCOUVER